2021
DOI: 10.1164/rccm.202102-0461oc
|View full text |Cite
|
Sign up to set email alerts
|

A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
26
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 58 publications
(26 citation statements)
references
References 46 publications
0
26
0
Order By: Relevance
“…69 The optimal length for PEx was the subject of the STOP-2 trial. 70 If a participant had at least 8% improvement in FEV1pp and 11-point decrease in CRISS by Days 7-10 of exacerbation, then 10 days of IV antibiotics was not inferior to 14 days. For those participants without an improvement at 7-10 days, 21 days of IV antibiotics was not superior to 14 days.…”
Section: Pulmonary Exacerbations (Pex)mentioning
confidence: 99%
See 1 more Smart Citation
“…69 The optimal length for PEx was the subject of the STOP-2 trial. 70 If a participant had at least 8% improvement in FEV1pp and 11-point decrease in CRISS by Days 7-10 of exacerbation, then 10 days of IV antibiotics was not inferior to 14 days. For those participants without an improvement at 7-10 days, 21 days of IV antibiotics was not superior to 14 days.…”
Section: Pulmonary Exacerbations (Pex)mentioning
confidence: 99%
“…The optimal length for PEx was the subject of the STOP‐2 trial 70 . If a participant had at least 8% improvement in FEV1pp and 11‐point decrease in CRISS by Days 7–10 of exacerbation, then 10 days of IV antibiotics was not inferior to 14 days.…”
Section: Introductionmentioning
confidence: 99%
“…The diagnosis and management of pulmonary exacerbations (PExs) remain a major topic of interest. STOP2 reported that shorter duration of antibiotic therapy for PExs is not inferior to longer courses [82] . Almost 1000 adult PwCF were enrolled and randomized based on their clinical response after 7–10 days of intravenous antibiotic treatment.…”
Section: Pulmonary Exacerbationsmentioning
confidence: 99%
“…Conflicting data on the effectiveness of CRP as a biomarker have been published. In the STOP2 study, CRP was not a good predictor for a PEx diagnosis, whereas others have proposed a step wise algorithm using CRP thresholds and fold-change from stable may be used to diagnose a PEx when there are conflicting data between changes in lung function and symptoms [ 82 , 85 ]. Whilst this review does not permit us to examine all potential biomarkers in detail, the Biomarker Special Interest Working Group published a review highlighting neutrophil elastase, IL-8, TNF-α and IL-1β as valid biomarkers of lung inflammation.…”
Section: Pulmonary Exacerbationsmentioning
confidence: 99%
“…Optimal length for PEx was the subject of the STOP-2 trial 69 . If a participant had at least 8% improvement in FEV1pp and 11-point decrease in CRISS by day 7-10 of exacerbation, then 10 days of IV antibiotics was not inferior to 14 days.…”
Section: Pulmonary Exacerbations (Pex)mentioning
confidence: 99%